Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India.
Intas' success and incessant growth lies in clinical execution of successful and strategic moves made in the areas of manufacturing, R & D, Biotechnology and global operations over three decades. As of 31st of March 2015, Intas has recorded a turnover of ~Rs.5150 crore* at 21% CAGR over the last 5 years and a profit growth of ~50% CAGR over the same period. Intas is currently ranked 10th in the Indian Pharma Market with 2.80% market share. (as per IMS Health India, Secondary Stockiest Audit (SSA), Nov 16, 2016 MAT).
In the domestic market, Intas is the 4th largest corporate in Indian Chronic Pharma Market with a market share of 5.32% (as per IMS SSA Nov' 16 MAT data). It also has presence in cardiovascular system (CVS), diabetology, gynecology, infertility, respiratory care, gastroenterology, pain management as well as other therapeutic segments.
Besides rapidly growing domestic prominence, Intas is also present in more than 70 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Africa, Australia, New Zealand, Asia - Pacific as well as CIS and MENA countries.
Intas' global strategy includes alliances with leading Global Pharma Companies for development and distribution of products as well as direct product distribution.
Intas has made a substantial commitment to its Biologics Business Unit in terms of creating R&D, manufacturing and marketing capabilities for its biotech portfolio. As on date, Intas commercialized 11 biologic products and continues its R&D efforts in chronic disease areas such as Oncology (Cancer), Rheumatology, Auto-Immune, Nephrology, Ophthalmology and Plasma derived product based therapies.
Continual R & D initiatives have strengthened niche and complex product offerings in India and International markets. Commercialized in India, three pharmaceutical formulations are based on the novel lipid based drug delivery system with studies ongoing to extend these products to International markets.
Intas has made strategic investments in ten manufacturing facilities, globally. Between them, these facilities have received approvals from various prominent international regulatory bodies, including U.S. Food and Drug Administration (FDA).
* 1 USD = 62.54 INR as of 31st Mar 2015.